| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
1 Department of Internal Medicine, and 2 Department of Pharmacology and Clinical Pharmacology Unit, Seoul National University College of Medicine, Seoul, Korea, and 3 Samyang Research Corporation, Salt Lake City, Utah
Purpose: The rationale for developing an alternative paclitaxel formulation concerns Cremophor EL-related side effects, and a novel paclitaxel delivery system might augment its therapeutic efficacy. Genexol-PM is a polymeric micelle formulated paclitaxel free of Cremophor EL. A phase I study was performed to determine the maximum tolerated dosage, dose-limiting toxicities, and the pharmacokinetic profile of Genexol-PM in patients with advanced, refractory malignancies.
Experimental Design: Twenty-one patients were entered into the study. Genexol-PM was i.v. administered over 3 h every 3 weeks without premedication. The Genexol-PM dose was escalated from 135 mg/m2 to 390 mg/m2.
Results: All of the patients were evaluable for toxicity and response. Acute hypersensitivity reactions were not observed. Neuropathy and myalgia were the most common toxicities. During cycle 1, grade 3 myalgia occurred in 1 patient at 230 and 300 mg/m2, respectively. At 390 mg/m2, 2 of 3 patients developed grade 4 neutropenia or grade 3 polyneuropathy. Therefore, the maximum tolerated dosage was determined to be 390 mg/m2. There were 3 partial responses (14%) among the 21 patients. Of the 3 responders, 2 were refractory to prior taxane therapy. The paclitaxel area under the curve from time 0 to infinity and peak or maximum paclitaxel concentration seemed to increase with escalating dose, except at 230 mg/m2, which suggests that Genexol-PM has linear pharmacokinetics.
Conclusion: The main dose-limiting toxicities were neuropathy, myalgia, and neutropenia, and the recommended dosage for a phase II study is 300 mg/m2. Genexol-PM is believed to be superior to conventional paclitaxel in terms of the obviation of premedication and the delivery of higher paclitaxel doses without additional toxicity.
This article has been cited by other articles:
|
|
 |
|
  H. Chen, S. Kim, L. Li, S. Wang, K. Park, and J.-X. Cheng Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging PNAS, May 6, 2008; 105(18): 6596 - 6601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin Therapeutic Nanoparticles for Drug Delivery in Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1310 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sutton, S. Wang, N. Nasongkla, J. Gao, and E. E. Dormidontova Doxorubicin and {beta}-Lapachone Release and Interaction with Micellar Core Materials: Experiment and Modeling Experimental Biology and Medicine, September 1, 2007; 232(8): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tang, G. Du, N. Wang, C. Liu, H. Hang, and W. Liang Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin J Natl Cancer Inst, July 4, 2007; 99(13): 1004 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Mita, A. J. Olszanski, R. C. Walovitch, R. P. Perez, K. MacKay, D. P. Tuck, C. Simmons, S. Hammond, M. M. Mita, M. Beeram, et al. Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel Clin. Cancer Res., June 1, 2007; 13(11): 3293 - 3301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hennenfent and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Onc., May 1, 2006; 17(5): 735 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Harries, P. Ellis, and P. Harper Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer J. Clin. Oncol., November 1, 2005; 23(31): 7768 - 7771. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Boddy, E. R. Plummer, R. Todd, J. Sludden, M. Griffin, L. Robson, J. Cassidy, D. Bissett, A. Bernareggi, M. W. Verrill, et al. A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules Clin. Cancer Res., November 1, 2005; 11(21): 7834 - 7840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mielke, A. Sparreboom, S. M. Steinberg, H. Gelderblom, C. Unger, D. Behringer, and K. Mross Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4843 - 4850. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
